CoChat

Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

Karsdal, M.A., Henriksen, K., Leeming, D.J., Mitchell, P., Duffin, K., Barascuk, N., Klickstein, L., Aggarwal, P., Nemirovskiy, O., Byrjalsen, I., Qvist, P., Bay-Jensen, A.C., Dam, E.B., Madsen, S.H., Christiansen, C. · 2009 · Biomarkers
Cited by 135

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

The aim of this review is to discuss the potential usefulness of a novel class of biochemical markers, neoepitopes, in the context of the US Food and Drug Administration (FDA) Critical Path Initiative, which emphasizes biomarkers of safety and efficacy as areas of pivotal interest. Examples of protein degradation fragments--neoepitopes--that have proven useful for research on bone and cartilage are collagen type I and collagen type II degradation products, respectively. These markers have utility in the translational approach, as they can be used to estimate safety and efficacy in both preclinical models and clinical settings. Biochemical markers of tissue degradation may provide optimal tools, which in combination with other techniques, prove essential to drug discovery and development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13547500902777608

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 135

Metadata

Authors
Karsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P., Duffin, K., Barascuk, N., Klickstein, L., Aggarwal, P., Nemirovskiy, O., Byrjalsen, I., Qvist, P., Bay-Jensen, A. C., Dam, E. B., Madsen, S. H., & Christiansen, C.
Venue
Biomarkers
Published
2009-05
Volume
14
Issue
3
Pages
181-202
ISSN
  • 1354-750X (ISSN-L)
  • 1366-5804
OpenAlex
W2132302127
Cited by
135
References
13
FWCI
5.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. https://app.cochat.ai/papers/10.1080/13547500902777608
The paper
Karsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P., Duffin, K., Barascuk, N., Klickstein, L., Aggarwal, P., Nemirovskiy, O., Byrjalsen, I., Qvist, P., Bay-Jensen, A. C., Dam, E. B., Madsen, S. H., & Christiansen, C. (2009). Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. https://doi.org/10.1080/13547500902777608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.